Glecirasib
Glecirasib (JAB-21822) is an oral KRAS G12C inhibitor that selectively targets and inactivates the mutant protein, blocking downstream oncogenic signaling. Preclinical studies in animal models demonstrate its antitumor efficacy and favorable safety profile, supporting its investigation in cancers driven by this mutation.
Product Specifications
CAS Number
2657613-87-9
Product Name Alternative
KRAS G12C inhibitor 36, JAB21822, JAB-21822, JAB-21000, JAB21000
Field of Research
Pharmacology & Drug Discovery, Signal Transduction
Purity
99.70% (May vary between batches)
Smiles
N#CC=1C (=O) N (C=2N=C (C (Cl) =CC2C1N3CCN (C (=O) C=C) CC3) C=4C (F) =C (F) C (F) =C (F) C4N) C=5C (=NC=CC5C) C (C) C
Molecular Formula
C31H26ClF4N7O2
Molecular Weight
640.03
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![3- ({[ (9H-Fluoren-9-yl) methoxy]carbonyl}amino) -3- (pyridin-4-yl) propanoic acid](https://cdn.genprice.uk/genprice/uk/genprice3.webp)
XPA14423-01 50 mg
3- ({[ (9H-Fluoren-9-yl) methoxy]carbonyl}amino) -3- (pyridin-4-yl) propanoic acid
Sign In for Pricing
View Details XPA14423-02 0.5 g
3- ({[ (9H-Fluoren-9-yl) methoxy]carbonyl}amino) -3- (pyridin-4-yl) propanoic acid
Sign In for Pricing
View Details 